Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis. [PDF]
Ther Adv Med OncolWang J +7 more
europepmc +1 more source
Utilization and predictors of use of immunomodulators for atopic dermatitis: A cohort study. [PDF]
JAAD IntAnand P +9 more
europepmc +1 more source
Clinical impact and cost-effectiveness of rapid versus non-rapid antiretroviral therapy initiation in HIV-positive men who have sex with men in China using modelling and 96-week multicenter cohort data. [PDF]
Sci RepZhou K, Wang X, Zhou D, Dai L, Tang W.
europepmc +1 more source
Commentary on "global disparities in healthcare resources and cancer burden: a population-based systematic analysis of 171 Countries in 2022". [PDF]
Int J SurgPezeshkian A.
europepmc +1 more source
Outcome measures in prehabilitation interventions for total hip and knee arthroplasty: A scoping review. [PDF]
Clin RehabilBurgess N +6 more
europepmc +1 more source
Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and Validation. [PDF]
PharmacoeconomicsGal P +7 more
europepmc +1 more source
Publisher Correction: Pricing for Multi-Indication Drugs in the Italian Regulatory Context. [PDF]
Pharmacoecon OpenUrsino MG +4 more
europepmc +1 more source
Real-World Evidence in Drug Approvals at the European Medicines Agency.
JAMA Netw OpenBachinger M +3 more
europepmc +1 more source
State and Federal Policy Solutions to Rising Prescription Drug Prices in the U.S. [PDF]
, 2019 Padula, William V.
core +1 more source
EQ-5D(-Y) Valuation from Adult and Child Perspectives: Where Does the Empirical Evidence Leave Us and How Should We Proceed? [PDF]
PharmacoeconomicsLipman SA, Guo Z.
europepmc +1 more source